The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday.